Home › Funds › ORBIMED ADVISORS LLC › KNSA
ORBIMED ADVISORS LLC position in KNSA
KINIKSA PHARMACEUTICALS INTL · Health Care
ORBIMED ADVISORS LLC reported holding 420,600 shares of KNSA (KINIKSA PHARMACEUTICALS INTL) in its Q2 2026 13F filing — a position valued at US$26.9M, representing 0.54% of its reported portfolio and ranking #46 among its reported holdings. ORBIMED ADVISORS LLC has disclosed KNSA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ORBIMED ADVISORS LLC's KNSA position evolved
ORBIMED ADVISORS LLC first disclosed a stake in KNSA in Q4 2025 at 187,199 shares (US$7.7M). The position peaked in Q2 2026 at 420,600 shares, worth US$26.9M. Across 3 filings, ORBIMED ADVISORS LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 420,600 shares valued at US$26.9M — an increase of 240,001 shares quarter over quarter.. Notable position changes include a 133% increase in Q2 2026 (shares rose 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 187.20K | $7.72M | New |
| Q1 2026 | 180.60K | $8.70M | Reduce |
| Q2 2026 | 420.60K | $26.90M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KNSA and 13F data
KNSA (KINIKSA PHARMACEUTICALS INTL) is a Health Care company. 48 other funds we track also report a position in KNSA — the largest reported positions include Rubric Capital Management LP (US$255.8M), BAKER BROS. ADVISORS LP (US$181.3M), TANG CAPITAL MANAGEMENT LLC (US$144.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KNSA
- Rubric Capital Management LP 4.00M sh · $255.79M · Q2 2026
- BAKER BROS. ADVISORS LP 2.83M sh · $181.28M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 2.26M sh · $144.52M · Q2 2026
- Spruce Street Capital LP 918.07K sh · $58.71M · Q2 2026
- RICE HALL JAMES & ASSOCIATES, LLC 624.93K sh · $39.96M · Q2 2026
- Penn Capital Management Company, LLC 368.11K sh · $23.57M · Q2 2026
- Soleus Capital Management, L.P. 246.35K sh · $15.75M · Q2 2026
- ESSEX INVESTMENT MANAGEMENT CO LLC 202.02K sh · $15.07M · Q3 2026
- ArrowMark Colorado Holdings LLC 215.55K sh · $13.78M · Q2 2026
- STEMPOINT CAPITAL LP 209.23K sh · $13.38M · Q2 2026
More on ORBIMED ADVISORS LLC
FAQ
How long has ORBIMED ADVISORS LLC held KNSA?
ORBIMED ADVISORS LLC has disclosed KNSA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is ORBIMED ADVISORS LLC's current position in KNSA?
As of Q2 2026, ORBIMED ADVISORS LLC holds 420.60K shares of KNSA (KINIKSA PHARMACEUTICALS INTL), valued at $26.90M, representing 0.54% of its reported portfolio and ranking #46.
Has ORBIMED ADVISORS LLC been buying or selling KNSA?
In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC increased its position in KNSA. The position peaked in Q2 2026 at 420.60K shares.
Which other funds hold KNSA?
Other major institutional holders of KNSA include Rubric Capital Management LP, BAKER BROS. ADVISORS LP, TANG CAPITAL MANAGEMENT LLC, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.